“Both urology and oncology key opinion leaders in Europe have expressed a desire to have PROVENGE available to their patients and it is evident that there is pre-market demand as the first”
“We have a commercially-favorable label in Europe, including PSA quartile analysis and positive correlation between immune response and overall survival. These data will allow for early positioning and strong messaging for our reimbursement dossiers.”
“We successfully reduced our costs of goods sold on a pro-forma basis to 51% in the fourth quarter”
“Our favorable label in Europe will allow for early positioning and strong messaging for our reimbursement dossiers”
“Recently held a constructive meeting with the FDA regarding automation of the PROVENGE manufacturing process; the Agency expressed its support for this effort”
“Automation is an important strategic driver to help lower COGS in U.S. and also more efficiently make PROVENGE available worldwide”
News 
Market Data 
Discover 
